Dynavax Technologies Co. (DVAX) Expected to Announce Quarterly Sales of $3.55 Million

Brokerages expect that Dynavax Technologies Co. (NASDAQ:DVAX) will report $3.55 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Dynavax Technologies’ earnings, with the highest sales estimate coming in at $4.10 million and the lowest estimate coming in at $3.00 million. Dynavax Technologies posted sales of $50,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 7,000%. The firm is expected to report its next quarterly earnings report after the market closes on Monday, November 5th.

According to Zacks, analysts expect that Dynavax Technologies will report full-year sales of $11.62 million for the current year, with estimates ranging from $7.96 million to $15.27 million. For the next financial year, analysts forecast that the company will report sales of $93.41 million, with estimates ranging from $88.23 million to $98.58 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.01). The company had revenue of $1.25 million for the quarter, compared to analyst estimates of $1.88 million. Dynavax Technologies had a negative return on equity of 72.31% and a negative net margin of 8,570.06%. The firm’s quarterly revenue was up 1094.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.41) earnings per share.

Several brokerages have commented on DVAX. Royal Bank of Canada lifted their target price on Dynavax Technologies to $26.00 and gave the stock an “outperform” rating in a report on Monday, October 22nd. BidaskClub raised Dynavax Technologies from a “strong sell” rating to a “sell” rating in a report on Thursday, October 11th. ValuEngine downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Monday, July 30th. Cantor Fitzgerald set a $30.00 target price on Dynavax Technologies and gave the stock a “buy” rating in a report on Friday, October 19th. Finally, Zacks Investment Research raised Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, July 24th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $28.25.

Several hedge funds have recently bought and sold shares of DVAX. Eagle Asset Management Inc. bought a new position in shares of Dynavax Technologies in the 2nd quarter worth about $35,054,000. PointState Capital LP bought a new stake in Dynavax Technologies in the 2nd quarter valued at about $28,800,000. Carillon Tower Advisers Inc. bought a new stake in Dynavax Technologies in the 2nd quarter valued at about $24,951,000. Senvest Management LLC increased its position in Dynavax Technologies by 52.7% in the 2nd quarter. Senvest Management LLC now owns 2,336,089 shares of the biopharmaceutical company’s stock valued at $35,625,000 after buying an additional 806,102 shares in the last quarter. Finally, Chicago Capital LLC increased its position in Dynavax Technologies by 48.3% in the 2nd quarter. Chicago Capital LLC now owns 1,294,104 shares of the biopharmaceutical company’s stock valued at $19,735,000 after buying an additional 421,446 shares in the last quarter. 82.23% of the stock is owned by hedge funds and other institutional investors.

Shares of DVAX opened at $10.83 on Friday. The stock has a market cap of $632.42 million, a price-to-earnings ratio of -6.26 and a beta of 0.29. Dynavax Technologies has a 12 month low of $9.63 and a 12 month high of $23.85. The company has a debt-to-equity ratio of 0.76, a quick ratio of 8.67 and a current ratio of 8.87.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

See Also: Why do corrections happen?

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply